Climb Bio Inc CLYM

$10.68 -0.37 (-3.35%)

Valuation

Market cap
634,668,000
Revenue TTM
$0
Net income TTM
$-59,850,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
954,500
Avg volume
1,467,878
Day's range
$10.64 – $11.25
Shares out
57,436,000
Stochastic %K
2%
Beta
-0.04
Analysts
Strong Sell
Price target
$27.86

Price

Company profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy...

Show more

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
866 857 2596
Website
https://climbbio.com
Address
20 William Street, Suite G50, Wellesley Hills, United States

Latest news

Stocktwits

coder79 Oct 6, 8:15 PM
Healthcare dip-pullback scan (6 Oct) $ALKS $HCSG $CLYM $IKT: all 17–40% off 52W highs, with MACD histogram rising 2+ bars and RSI turning up from the 30s–40s. Entry trigger: buy only on a break above the prior day's high, with volume above average. Stop: below the recent swing low. No trigger, no trade. Dip bought on confirmation, not on a falling knife. 📈 Not financial advice. #swingtrading #healthcare
0 replies
Quantumup Oct 5, 11:03 AM
Raymond James reiterated $CLYM Strong Buy-$34 after the Co. announced an abstract for initial P2 budoprutug data in primary membranous nephropathy (PMN) to be presented at ASN Kidney Week on 10/24. $VERA $TVTX RHHBY BIIB VRTX Here's what Raymond James said: https://x.com/Quantumup1/status/2107064025477505372?s=20
0 replies
1234zerp Oct 2, 1:35 PM
$CLYM Preliminary Data from PrisMN, a Phase 2 Study Evaluating the Safety and Efficacy of Budoprutug, an Investigational Low-Fucosylated Anti-CD19 Monoclonal Antibody (mAb), in Patients with Primary Membranous Nephropathy (PMN) - https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4556952
1 replies
topstockalerts Oct 1, 8:38 PM
Raymond James updated its healthcare “top picks” list for October, adding Xencor and Calyxt while replacing Relay Therapeutics and Tyra Biosciences, respectively. The firm also added UnitedHealth Group, replacing Oscar Health. For Xencor, Raymond James cited upcoming data at the ESMO conference in late October as a potential near-term catalyst. The firm is watching for a positive readout and a clearer path toward pivotal development of XmAb819 in clear-cell renal cell carcinoma. Calyxt was added as its pipeline becomes more de-risked. The company expects to report initial Phase 2 data for CLYM116 next year, potentially providing further evidence on efficacy and dosing in IgA nephropathy before a Phase 3 study. Additional budoprutug data are expected in the fourth quarter of 2026 across pMN, ITP and SLE, three high-value indications. Raymond James also highlighted budoprutug’s potential subcutaneous formulation. $XNCR $CLYM
0 replies
1234zerp Oct 1, 3:18 PM
$CLYM ASN Absracts tomorrow
0 replies
Quantumup Sep 8, 11:54 AM
Oppenheimer⬆️ $CLYM's PT to $25, stays Outperform and said -- The recent CLYM116 reveal illustrates a best-in-class clinical profile for IgAN as echoed by our KOL discussion. $JBIO $OTSKY VERA TVTX NVS VRTX TAK IONS ALNY - REGN SNY AMGN UCBJY H.C. Wainwright⬆️ Climb Bio's PT to $30 and reiterated Buy. Here's what Oppenheimer went on to say and what H.C. Wainwright said in their notes to investors: https://x.com/Quantumup1/status/2097292170218586505?s=20
0 replies
topstockalerts Sep 8, 12:02 AM
$CLYM this one keeps refusing to break character.
0 replies
Quantumup Sep 4, 1:06 PM
Piper Sandler⬆️ $CLYM's PT to $40 from $23, reit'd Overweight and said that CLYM116 data surpassed expectations—validated a best-in-class product profile. $JBIO $OTSKY VERA TVTX NVS VRTX TAK IONS ALNY -REGN SNY AMGN UCBJY BRiley⬆️ Climb Bio's PT to $30 from $26, reit'd Buy and said that CLYM116 data landed at our base case—the sweeper mechanism differentiation for CLYM116 showed where it matters.
0 replies